OCALA, FL (352today.com) – Obesity and weight management are major health issues that affect millions of people, and in communities like Ocala and surrounding areas, the problem is just as prevalent.
At Ocala Plastic Surgery & Dermatology, Andrea Flynn, a skilled Physician Assistant-Certified (PA-C), has created the Signature Weight Loss Program to help patients achieve their weight-related health goals. With over a decade of aesthetics experience and a strong background in primary care, Flynn is proficient in managing diabetic medications and weight-loss therapies, including the innovative drug Tirzepatide.
A deeper look into Tirzepatide and weight loss
Tirzepatide is a major step forward in treating obesity. “Tirzepatide is a weekly injectable GLP-1/GIP inhibitor that works with the pancreas to stabilize blood sugars and insulin. It slows gastric emptying and helps patients feel fuller which can aid in weight loss,” says Flynn. “These medications are now used for weight loss and not just for diabetics.”
In comparison, while Semaglutide is a GLP-1 inhibitor, Tirzepatide’s ability to act on both GLP-1 and GIP gives it a stronger advantage in treating obesity, Flynn explains. “Ideally, Tirzepatide is recommended for obese patients with a BMI of 30 or higher,” says Flynn. “Or for patients with a BMI of 27 and comorbidities such as high blood pressure, high cholesterol and/or prediabetes.” She adds that patient selection is personalized, so some individuals outside these criteria may still qualify.
The importance of individualized care
Personalized care is at the forefront of a Tirzepatide weight loss program, asserts Flynn. Patients go through careful screening and thorough lab tests to see if they can join the weight loss program. Some people may not qualify due to specific health issues related to Tirzepatide. For those who are eligible, she mentions that possible side effects include stomach problems and a higher risk of conditions like pancreatitis.
The advantages can be significant since patients often see a decrease in appetite shortly after beginning the treatment. “Patients typically notice decreased appetite within a couple of days, up to a week,” Flynn says. “Weight loss goals are one to two pounds per week.” Additionally, Flynn states that a weight loss program with Tirzepatide is backed by a full plan that offers nutrition education and exercise routines to promote long-term healthy habits.
Long-term commitment to health
It’s emphasized that weight reduction through Tirzepatide is not a fleeting solution but a commitment to a healthier lifestyle. Prospective individuals should be ready to adopt longer-term changes and not view the program as a quick fix for short-term weight loss goals. Flynn says that patients receive continued support and monitoring, including regular follow-up appointments, to ensure successful and healthy weight management.